Markus Warmuth
Chief Executive Officer en MONTE ROSA THERAPEUTICS, INC. .
Fortuna: 3 M $ al 31/03/2024
Perfil
Markus Warmuth is currently the Chief Executive Officer of Monte Rosa Therapeutics AG and the President, Chief Executive Officer & Director of Monte Rosa Therapeutics, Inc. He is also an Independent Director at IMV, Inc. and a Director at Ventus Therapeutics, Inc. and Ventus Therapeutics U.S., Inc. Additionally, he is a Venture Partner at Versant Venture Management LLC.
Previously, he served as the President & Chief Executive Officer of H3 Biomedicine, Inc. from 2011 to 2018.
He was also a Director at Relay Therapeutics, Inc. from 2018 to 2019.
Dr. Warmuth holds a doctorate degree from Ludwig-Maximilians-Universität München.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 02/01/2024 | 416 538 ( 0.83% ) | 3 M $ | 31/03/2024 | |
IMV INC.
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/12/2023 |
Cargos activos de Markus Warmuth
| Empresas | Cargo | Inicio |
|---|---|---|
| IMV INC. | Director/Board Member | 06/11/2018 |
| MONTE ROSA THERAPEUTICS, INC. | Chief Executive Officer | 01/01/2020 |
Monte Rosa Therapeutics AG
 Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Chief Executive Officer | - |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private Equity Investor | 01/01/2020 |
Ventus Therapeutics, Inc.
 Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ventus Therapeutics, Inc. operates as a biopharmaceutical company. It focuses in developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer. The company was founded by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao and is headquartered in Montreal, Canada. | Director/Board Member | 07/12/2021 |
Ventus Therapeutics U.S., Inc.
 Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Ventus Therapeutics U.S., Inc. operates as a biotechnology company. The company is headquartered in Natick, MA. | Director/Board Member | 07/12/2021 |
Antiguos cargos conocidos de Markus Warmuth.
| Empresas | Cargo | Fin |
|---|---|---|
| RELAY THERAPEUTICS, INC. | Director/Board Member | 01/08/2019 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Chief Executive Officer | 01/05/2018 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formación de Markus Warmuth.
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| IMV INC. | Health Technology |
| RELAY THERAPEUTICS, INC. | Health Technology |
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 7 |
|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Monte Rosa Therapeutics AG
Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Health Technology |
Ventus Therapeutics, Inc.
Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ventus Therapeutics, Inc. operates as a biopharmaceutical company. It focuses in developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer. The company was founded by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao and is headquartered in Montreal, Canada. | Health Technology |
Ventus Therapeutics U.S., Inc.
Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Ventus Therapeutics U.S., Inc. operates as a biotechnology company. The company is headquartered in Natick, MA. | Distribution Services |
- Bolsa de valores
- Insiders
- Markus Warmuth
